SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–Allegro Ophthalmics completes enrollment in stage 2 of its DEL MAR trial evaluating the safety and efficacy of Luminate in combination and as an adjunctive therapy with anti-VEGFs in patients with DME
Category: News
Female hormones increase risk of vision loss in rare genetic disease
Girls with a rare genetic disorder caused by mutations in a gene known as Nf1 are much more likely to lose their vision than boys with mutations in the same gene.
Telemedicine eye screening programs could help bridge gap in caring for premature babies
Retinopathy of prematurity (ROP) occurs when abnormal blood vessels grow over the retina and may lead to blindness in premature babies.
Global Ophthalmic Lasers Market Analysis 2016 – Forecast to 2022 – By Laser Type, Application & End User – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Ophthalmic Lasers Market Analysis 2016 – Forecast to 2022” report to their offering. This analysis is one of the most accurate studies performed using the combinati…
Global Ophthalmic Lasers Market Analysis 2016 – Forecast to 2022 – By Laser Type, Application & End User – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Ophthalmic Lasers Market Analysis 2016 – Forecast to 2022” report to their offering. This analysis is one of the most accurate studies performed using the combinati…
Study examines potential effect of regular marijuana use on vision
A small, preliminary study has found an abnormality involving the retina that may account for altered vision in regular cannabis users. The results are published online by JAMA Ophthalmology.
Samenvatting: Neurotrofische keratitis: EMA aanvaardt aanvraag verkoopverguning van Dompé voor oogdruppels met Cenegermin (Oxervate®)
MILAAN–(BUSINESS WIRE)–Het biofarmaceutische bedrijf Dompé heeft bekendgemaakt dat zijn verzoek bij het Europees Geneesmiddelenbureau voor de oogdruppels Oxervate tegen matige tot ernstige neurotrofische keratitis is aanvaard. De aanvaarding door het Europees Geneesmiddelenbureau is het begin van een wetenschappelijk beoordelingsproces van het dossier, met het uiteindelijke doel een vergunning voor de verkoop van het medicinale product te verkrijgen. Het product is in 2015 aangemerkt als wees
Acucela Secures Option to Exclusively Acquire Novel Retinal Technology
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, and EyeMedics, LLC, a drug development company focusing on small molecule therapeutics for the eye, announced today an R&D agreement and exclusive option to acquire the global r
New Risks Posed by Vancomycin Use in Cataract Surgery
Dr Roger Steinert shares the latest information on hemorrhagic occlusive retinal vasculitis, a new and potentially devastating complication. Medscape Ophthalmology
Morning Break: ‘Poorly Trained Surgeon’; Generic Tamiflu; Tiny Reindeer
(MedPage Today) — Health news and commentary from around the Web, gathered by the MedPage Today staff
Kératite neurotrophique : l’EMA valide le dossier de demande d’autorisation de mise sur le marché pour le collyre Cenegermin (Oxervate®) déposé par Dompé
MILAN–(BUSINESS WIRE)–La société biopharmaceutique Dompé a annoncé la validation de la demande d’enregistrement soumise à l’Agence européenne des médicaments (EMA) pour le collyre Oxervate®, pour le traitement de la kératite neurotrophique modérée à sévère chez les patients adultes. La validation de ce dossier par l’EMA constitue la première étape de la procédure d’évaluation scientifique permettant d’obtenir l’autorisation de mise sur le marché du traitement, qui a été désigné comme médicame
Cheratite neurotrofica: EMA valida la richiesta di autorizzazione in commercio di cenegermin gocce oculari (Oxervate®) presentata da Dompé
MILANO–(BUSINESS WIRE)–L’azienda biofarmaceutica Dompé annuncia oggi la validazione della domanda di registrazione presentata all’Agenzia Europea dei Medicinali (EMA) di Oxervate® gocce oculari, proposto per il trattamento della cheratite neurotrofica moderata e grave in pazienti adulti. La validazione da parte di EMA segna l’inizio della procedura di revisione scientifica del dossier al fine di ottenere l’autorizzazione al commercio del farmaco, già designato nel 2015 farmaco orfano per il t
Neurotrophe Keratopathie: EMA prüft den von Dompé eingereichten Zulassungsantrag für Cenegermin–Augentropfen (Oxervate®)
MAILAND–(BUSINESS WIRE)–Das Biopharma-Unternehmen Dompé gab bekannt, dass die Europäische Arzneimittel-Agentur (EMA) den eingereichten Zulassungsantrag für Oxervate®-Augentropfen angenommen hat. Diese Augentropfen wurden zur Behandlung der mittelschweren und schweren neurotrophen Keratopathie (neurotrophen Keratitis) bei erwachsenen Patienten entwickelt. Mit dieser Annahme durch die EMA erfolgt die Einleitung des wissenschaftlichen Prüfverfahrens, das über die Zulassung zur Vermarktung entsch
Neurotrophic Keratitis: EMA Validates the Marketing Authorisation Application for Cenegermin Eye Drops (Oxervate®) Submitted by Dompé
MILAN–(BUSINESS WIRE)–The biopharmaceutical company Dompé announced the acceptance of the registration application submitted to the European Medicines Agency (EMA) for Oxervate® eye drops, for the treatment of moderate and severe neurotrophic keratitis in adult patients. Acceptance by EMA constitutes the initiation of the dossier’s scientific review procedure, in order to obtain authorisation to market the medicinal product, which was designated an orphan drug for the treatment of neurotrophi
Queratitis neurotrófica: La EMA valida la solicitud de autorización de comercialización para el colirio Cenegermin (Oxervate®) presentado por Dompé
MILÁN–(BUSINESS WIRE)–La empresa biofarmacéutica Dompé ha anunciado hoy la aceptación de la solicitud de inscripción presentada a la Agencia Europea de Medicamentos (European Medicines Agency, EMA) para el colirio Oxervate®, para el tratamiento de queratitis neurotrófica de moderada a grave en pacientes adultos. La aceptación por parte de la EMA supone el inicio del procedimiento de revisión científica del expediente con el fin de conseguir la autorización para la comercialización del medicam
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced that the primary endpoint was not achieved in its two pivotal Phase 3 clinical trials investigating Fovista® (pegpleranib).
Home-visit based vision rehabilitation can improve lives of partially-sighted people
The visual function and daily life of people whose sight can’t be corrected with glasses or contact lenses can be significantly improved through home visits by rehabilitation specialists, concludes a study by Cardiff University.
Antihypertensive Meds May Protect Against Glaucoma
“Antiadrenergic drugs seem to have the greatest protective effect,” say researchers, noting perhaps cardiologists and ophthalmologists should work jointly in prevention or treatment of some eye diseases.
Heartwire from Medscape
New contact lens therapy effective in slowing progression of juvenile-onset myopia, study shows
A groundbreaking contact lens therapy has potential to impact the fast-growing issue of myopia (nearsightedness) among children, based on research presented at the American Academy of Optometry’s 95th Annual Meeting.
Habitual Cannabis Use May Slow Visual Perception
An electrophysiology study of retinal cell function finds altered processing with substantial delay in the transmission of action potentials by the ganglion cells in regular cannabis users. Medscape Medical News